Open AccessOtilonium bromide in irritable bowel syndrome: A dose-ranging randomized double-blind placebo-controlled trial
Author(s) -
Danuta Chmielewska-Wilkoń
Publication year - 2014
Publication title -
world journal of gastroenterology
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.427
H-Index - 155
eISSN - 2219-2840
pISSN - 1007-9327
DOI - 10.3748/wjg.v20.i34.12283
Subject(s) - placebo , medicine , irritable bowel syndrome , bloating , abdominal pain , gastroenterology , placebo controlled study , defecation , diarrhea , dose ranging study , double blind , pathology , alternative medicine
To examine the efficacy and safety of otilonium bromide (OB) in treatment-sensitive functional irritable bowel syndrome (IBS) clinical parameters.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom